Phaseline

Targets › F7

F7 (Coagulation factor VII): drug programs, companies and trials

10 programs from 9 companies in 13 trials: 6 Phase 4, 4 Phase 3, 3 Phase 2; Hematology, Cardiovascular, Neurology; next expected readout Dec 2026.

Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. (UniProt, P08709)

Open in Phaseline: the race on F7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
American Thrombosis and Hemostasis Networkcoagulation factor VIIa [recombinant]-jncw (SEVENFACT)
Recombinant activated human factor VII (rhFVIIa) - cofactor for the extrinsic coagulation
F7Phase 4Hemophilia A With InhibitorMar 2027
Novo NordiskEptacog Alfa (Activated)
Coagulation factor VII exogenous protein
F7Phase 4Severe Postpartum HaemorrhageAug 2027
Children's Hospital Los AngelesFeiba
Activated prothrombin complex concentrate (aPCC) - contains vitamin K-dependent clotting f
F2, F7, F10Phase 4Hemophilia A With Inhibitor–
CSL BehringProthrombin Complex Concentrate (BE1116)
Coagulation factor VII exogenous protein; Vitamin K-dependent protein S exogenous protein; Vitamin K-dependent protein C exogenous protein
F7, PROS1, PROC, F9, F2Phase 3Complex Cardiovascular Surgery With Cardiopulmonary Bypass; Cardiac Valve Disease; Hemophilia; Liver CirrhosisApr 2027
Joseph Broderick, MDRecombinant Activated Factor VII (rFVIIa)
Recombinant activated coagulation factor VII; promotes hemostasis by activating tissue fac
F7Phase 3Intracerebral HemorrhageJan 2028
Joseph Broderick, MDRecombinant Factor VIIa (rFVIIa)
Recombinant tissue factor pathway inhibitor; activates factor X to generate thrombin for h
F7Phase 3Intracerebral HemorrhageJan 2029
Icahn School of Medicine at Mount SinaiOral Anticoagulant (OAC) - Vitamin K Antagonist (VKA) or Direct Oral Anticoagula
Vitamin K antagonist or factor Xa/IIa inhibitor anticoagulation
F2, F7, F9, F10Phase 3Atrial Fibrillation–
Emory UniversityEptacog beta (SEVENFACT®; EB)
Recombinant coagulation factor VIIa
F7Phase 2Glanzmann ThrombastheniaDec 2026
Hemab ApSSutacimig
Bispecific antibody binding activated factor VII and TLT-1 on platelets
F7, TREML1Phase 2Congenital Factor VII DeficiencyNov 2027
Northwell HealthFEIBA
Factor VIII inhibitor bypass activity - prothrombin complex concentrate containing factors
F2, F7, F9, F10Phase 2Cardiac DiseaseNov 2028

Conditions

Hemophilia A With Inhibitor (2) Intracerebral Hemorrhage (2) Glanzmann Thrombasthenia (1) Severe Postpartum Haemorrhage (1) Congenital Factor VII Deficiency (1) Cardiac Disease (1) Atrial Fibrillation (1) Complex Cardiovascular Surgery With Cardiopulmonary Bypass (1) Cardiac Valve Disease (1) Hemophilia (1) Liver Cirrhosis (1)

Modalities

small molecule (5), protein or peptide (4), antibody (1)

Companies

Joseph Broderick, MD (2) Emory University (1) Novo Nordisk (1) Hemab ApS (1) American Thrombosis and Hemostasis Network (1) Northwell Health (1) Icahn School of Medicine at Mount Sinai (1) CSL Behring (1) Children's Hospital Los Angeles (1)

Related targets

F2 (4) F9 (3) F10 (3) TREML1 (1) PROS1 (1) PROC (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.